Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BACE1 | P56817 | 1/20 | 0.67 |
| ▸ | MCHR1 | Q99705 | 3/20 | 0.53 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.48 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.48 |
| ▸ | HRH3 | Q9Y5N1 | 7/20 | 0.46 |
| ▸ | CYP2D6 | P10635 | 3/20 | 0.46 |
| ▸ | HRH1 | P35367 | 1/20 | 0.46 |
| ▸ | CYP26A1 | O43174 | 1/20 | 0.44 |
| ▸ | FFAR1 | O14842 | 1/20 | 0.44 |
| ▸ | FAAH | O00519 | 4/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1269557 | 1.00 | BACE1 (0.67) | BACE1MCHR1ITGB3ITGA2BHRH3 | |
| Hydrochloric Acid SCHEMBL4622556 | 0.99 | BACE1 (0.66) | BACE1MCHR1ITGB3ITGA2BHRH3 | |
| Water SCHEMBL4978875 | 0.99 | BACE1 (0.66) | BACE1MCHR1ITGB3ITGA2BHRH3 | |
| Hydrochloric Acid SCHEMBL1269523 | 0.98 | BACE1 (0.65) | BACE1MCHR1ITGB3ITGA2BHRH3 | |
| Hydrochloric Acid SCHEMBL4345712 | 0.98 | BACE1 (0.65) | BACE1MCHR1ITGB3ITGA2BHRH3 | |
| SCHEMBL14440137 | 0.95 | BACE1 (0.64) | BACE1MCHR1ITGB3ITGA2BHRH3 | |
| Hydrochloric Acid SCHEMBL4621212 | 0.94 | BACE1 (0.63) | BACE1MCHR1ITGB3ITGA2BHRH3 | |
| SCHEMBL14440124 | 0.94 | BACE1 (0.65) | BACE1MCHR1ITGB3ITGA2BHRH3 | |
| Hydrochloric Acid SCHEMBL4621171 | 0.93 | BACE1 (0.64) | BACE1MCHR1ITGB3ITGA2BHRH3 | |
| SCHEMBL14440125 | 0.93 | BACE1 (0.64) | BACE1MCHR1ITGB3ITGA2BHRH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1270545-B1 | PROCESS FOR PRODUCING AMINE DERIVATIVES | TAKEDA PHARMACEUTICAL (JP) | 2008-11-05 | — | — | EP | claimed |
| US-20050228020-A1 | Beta secretase inhibitors | MIYAMOTO MASAOMI | 2005-10-13 | — | — | US | claimed |
| US-11559528-B2 | BACE1 inhibition for the treatment of cancer | THE CLEVELAND CLINIC FOUNDATION (US) | 2023-01-24 | — | — | US | disclosed |
| US-20210069205-A1 | BACE1 INHIBITION FOR THE TREATMENT OF CANCER | THE CLEVELAND CLINIC FOUNDATION | 2021-03-11 | — | — | US | disclosed |
| US-10098866-B2 | Pharmaceutical preparation containing copolyvidone | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2018-10-16 | — | — | US | disclosed |
| US-20180256720-A1 | COMPOSITIONS AND METHODS FOR TREATING HIV-ASSOCIATED NEUROCOGNITIVE DISORDERS | THE FLORIDA INTERNATIONAL UNIVERSITY BOARD OF TRUSTEES (US) | 2018-09-13 | — | — | US | disclosed |
| US-20170020841-A1 | PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE | TAKEDA PHARMACEUTICALS CO (JP) | 2017-01-26 | — | — | US | disclosed |
| EP-1801232-B1 | METHOD OF SCREENING TRANSMEMBRANE ENZYME INHIBITORY SUBSTANCE | TAKEDA PHARMACEUTICAL (JP) | 2012-03-14 | — | — | EP | disclosed |
| EP-2305219-A1 | Pharmaceutical preparations coated with a copolyvidone-containing coating | Takeda Pharmaceutical Company Limited (JP) | 2011-04-06 | — | — | EP | disclosed |
| US-20090274733-A1 | Pharmaceutical preparation containing copolyvidone | TAKEDA PHARMACEUTICAL COMPANY, LTD (JP) | 2009-11-05 | — | — | US | disclosed |
| US-20080220445-A1 | Method of Screening Transmembrane Enzyme Inhibitory Substance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-11 | — | — | US | disclosed |
| US-20080220445-A1 | Method of Screening Transmembrane Enzyme Inhibitory Substance | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2008-09-11 | — | — | US | disclosed |
| EP-1801232-A1 | METHOD OF SCREENING TRANSMEMBRANE ENZYME INHIBITORY SUBSTANCE | Takeda Pharmaceutical Company Limited (JP) | 2007-06-27 | — | — | EP | disclosed |
| US-20050085553-A1 | Remedies for mild recognition deflict | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2005-04-21 | — | — | US | disclosed |
| EP-1459764-A1 | REMEDIES FOR MILD RECOGNITION DEFLICT | Takeda Chemical Industries, Ltd. (JP) | 2004-09-22 | — | — | EP | disclosed |
| US-20040018239-A1 | Pharmaceutical preparation containing copolyvidone | TAKEDA PHARMACEUTICAL COMPANY LIMITED (JP) | 2004-01-29 | — | — | US | disclosed |
| EP-1334732-A1 | PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE | Takeda Chemical Industries, Ltd. (JP) | 2003-08-13 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (8 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170020841-A1 | PHARMACEUTICAL PREPARATION CONTAINING COPOLYVIDONE | PRCP, COPS6, COPS5 | BACE1 4855/4885MCHR1 1553/4885ITGB3 3211/4885 |
| US-11559528-B2 | BACE1 inhibition for the treatment of cancer | BACE1, BACE2, APP | BACE1 1/4885MCHR1 4515/4885ITGB3 2766/4885 |
| US-20090274733-A1 | Pharmaceutical preparation containing copolyvidone | PRCP, COPS6, COPS5 | BACE1 4855/4885MCHR1 1553/4885ITGB3 3211/4885 |
| US-20040018239-A1 | Pharmaceutical preparation containing copolyvidone | PRCP, COPS6, COPS5 | BACE1 4855/4885MCHR1 1553/4885ITGB3 3211/4885 |
| US-20050085553-A1 | Remedies for mild recognition deflict | ACHE, CHAT, PSEN1 | BACE1 6/4885MCHR1 1973/4885ITGB3 4360/4885 |
| US-10098866-B2 | Pharmaceutical preparation containing copolyvidone | PRCP, COPS6, COPS5 | BACE1 4855/4885MCHR1 1553/4885ITGB3 3211/4885 |
| US-20210069205-A1 | BACE1 INHIBITION FOR THE TREATMENT OF CANCER | BACE1, BACE2, APP | BACE1 1/4885MCHR1 4515/4885ITGB3 2766/4885 |
| US-20050228020-A1 | Beta secretase inhibitors | BACE1, BACE2, APP | BACE1 1/4885MCHR1 1502/4885ITGB3 2638/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.